Objective:

To explore the role of liquid biopsy comprehensive genomic profiling (CGP) in lung and breast cancer, emphasizing its potential to improve patient outcomes and integration into clinical practice.

Key Findings:

• Liquid biopsy CGP complements traditional tissue testing.
• It provides clinical value in lung and breast cancer pathways.
• Earlier molecular insights from liquid biopsies can lead to faster treatment decisions.
• Real-world implementation in Wales highlights workflow integration and challenges, including specific case studies.

Interpretation:

Liquid biopsy CGP is a valuable tool in cancer management, enhancing decision-making and patient outcomes through timely molecular insights.

Limitations:

• Operational challenges in liquid biopsy adoption, such as logistical issues and training needs.
• Clinical challenges related to the integration of new testing methods, including physician acceptance and patient access.

Conclusion:

Liquid biopsy offers significant advantages in cancer profiling and treatment planning, though challenges remain in its widespread adoption that must be addressed for optimal patient care.